Rein Therapeutics Inc. (RNTX) Research

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.

Market snapshot

Symbol
RNTX
Price
$0.92
Day change
+5.87%
Market cap
$25.6M
P/E ratio
-0.55x
52-week range
0.864-2.18
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Next earnings
in 2 months
Analyst price target
$6.00

Peer companies

  • Actinium Pharmaceuticals, Inc. (ATNM)
  • BioAtla, Inc. (BCAB)
  • HeartBeam, Inc. (BEAT)
  • Celularity Inc. (CELU)
  • Kezar Life Sciences, Inc. (KZR)
  • Mersana Therapeutics, Inc. (MRSN)
  • Inotiv, Inc. (NOTV)
  • Quantum BioPharma Ltd. (QNTM)

Recent insider activity

  • VON RICKENBACH JOSEF H — P-Purchase (4500 shares) on 2026-05-27
  • VON RICKENBACH JOSEF H — P-Purchase (23190 shares) on 2026-05-26
  • VON RICKENBACH JOSEF H — P-Purchase (15950 shares) on 2026-05-22
  • VON RICKENBACH JOSEF H — P-Purchase (3420 shares) on 2026-05-21
  • WINDSOR JAMES BRIAN — A-Award (150000 shares) on 2026-05-08

Open Rein Therapeutics Inc. (RNTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.